SEC Form 4 · accession 0001209191-15-047728
PHARMACYCLICS INC · PCYC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric H Halvorson
Director
Period of report
May 26, 2015
Accepted (ET)
May 28, 2015 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000949699
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 26, 2015 | U | 1,000 | $261.25 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $14.26 | May 26, 2015 | D | 12,500 | D | — | Dec 15, 2021 | Common Stock | 12,500 | 0 | D |
| Stock Option (Right to Buy)F2 | $59.28 | May 26, 2015 | D | 515 | D | — | Jul 2, 2022 | Common Stock | 515 | 0 | D |
| Stock Option (Right to Buy)F2 | $65.56 | May 26, 2015 | D | 466 | D | — | Oct 1, 2022 | Common Stock | 466 | 0 | D |
| Stock Option (Right to Buy)F2 | $49.00 | May 26, 2015 | D | 7,500 | D | — | Nov 9, 2022 | Common Stock | 7,500 | 0 | D |
| Stock Option (Right to Buy)F2 | $61.44 | May 26, 2015 | D | 522 | D | — | Jan 2, 2023 | Common Stock | 522 | 0 | D |
| Stock Option (Right to Buy)F2 | $79.67 | May 26, 2015 | D | 344 | D | — | Apr 1, 2023 | Common Stock | 344 | 0 | D |
| Stock Option (Right to Buy)F2 | $74.48 | May 26, 2015 | D | 3,750 | D | — | May 9, 2023 | Common Stock | 3,750 | 0 | D |
| Stock Option (Right to Buy)F2 | $85.39 | May 26, 2015 | D | 340 | D | — | Jul 1, 2023 | Common Stock | 340 | 0 | D |
| Stock Option (Right to Buy)F2 | $139.89 | May 26, 2015 | D | 195 | D | — | Oct 1, 2023 | Common Stock | 195 | 0 | D |
| Stock Option (Right to Buy)F2 | $108.44 | May 26, 2015 | D | 252 | D | — | Jan 2, 2024 | Common Stock | 252 | 0 | D |
| Stock Option (Right to Buy)F2 | $107.42 | May 26, 2015 | D | 267 | D | — | Apr 1, 2024 | Common Stock | 267 | 0 | D |
| Stock Option (Right to Buy)F2 | $95.08 | May 26, 2015 | D | 3,750 | D | — | May 9, 2024 | Common Stock | 3,750 | 0 | D |
| Stock Option (Right to Buy)F2 | $89.58 | May 26, 2015 | D | 440 | D | — | Jul 1, 2024 | Common Stock | 440 | 0 | D |
| Stock Option (Right to Buy)F2 | $115.80 | May 26, 2015 | D | 327 | D | — | Oct 1, 2024 | Common Stock | 327 | 0 | D |
| Stock Option (Right to Buy)F2 | $124.46 | May 26, 2015 | D | 306 | D | — | Jan 2, 2025 | Common Stock | 306 | 0 | D |
| Stock Option (Right to Buy)F2 | $257.015 | May 26, 2015 | D | 187 | D | — | Apr 7, 2025 | Common Stock | 187 | 0 | D |
Explanation of responses
- F1Price reflects aggregate per share consideration paid pursuant to the Tender Offer.
- F2Pursuant to terms of the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie this option was cancelled in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.